Literature DB >> 22873102

Toll-like receptor 4 signaling promotes the immunosuppressive cytokine production of human cervical cancer.

Y X Cheng1, X Y Qi, J L Huang, M Hu, L M Zhou, B S Li, X X Xu.   

Abstract

OBJECTIVES: To investigate the expression of TLR-4 (toll-like receptor) on human cervical cancer and find the biological function of the TLR-4 signal system.
METHODS: The immunohistochemistry method was performed to study the protein expression and distribution of TLR-4. The viability of HeLa cells was determined by cell viability assay. Cell proliferation was detected by FCM, ELISA and Western blot were used to observe the gene and protein expression of IL-6 and TGF-beta1 in Hela cell lines.
RESULTS: TLR-4 was over-expressed in cervix cancer, and its activation by LPS promotes proliferation and anti-apoptosis in Hela cells in vitro. Moreover the cell line proliferation increased in a dose- and time-dependent manner. The production of IL-6 and TGF-beta1 were promoted through the activation of the NF-kappaB signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22873102

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  10 in total

1.  TLR4-MyD88-TRAF6-TAK1 Complex-Mediated NF-κB Activation Contribute to the Anti-Inflammatory Effect of V8 in LPS-Induced Human Cervical Cancer SiHa Cells.

Authors:  Aiqin He; Rui Ji; Jia Shao; Chenyun He; Ming Jin; Yunzhao Xu
Journal:  Inflammation       Date:  2016-02       Impact factor: 4.092

2.  A systems biology analysis of the changes in gene expression via silencing of HPV-18 E1 expression in HeLa cells.

Authors:  Andres Castillo; Lu Wang; Chihaya Koriyama; Yoshito Eizuru; King Jordan; Suminori Akiba
Journal:  Open Biol       Date:  2014-10       Impact factor: 6.411

3.  TLR4 promotes the expression of HIF-1α by triggering reactive oxygen species in cervical cancer cells in vitro-implications for therapeutic intervention.

Authors:  Xiao Yang; Gan Tao Chen; Yan Qing Wang; Shu Xian; Li Zhang; Shao Ming Zhu; Feng Pan; Yan Xiang Cheng
Journal:  Mol Med Rep       Date:  2017-11-20       Impact factor: 2.952

Review 4.  Viral Modulation of TLRs and Cytokines and the Related Immunotherapies for HPV-Associated Cancers.

Authors:  Marconi Rego Barros; Talita Helena Araújo de Oliveira; Cristiane Moutinho Lagos de Melo; Aldo Venuti; Antonio Carlos de Freitas
Journal:  J Immunol Res       Date:  2018-05-02       Impact factor: 4.818

5.  Myeloid-derived suppressor cells and associated events in urethane-induced lung cancer.

Authors:  Daniela Teixeira; Joaquim Soares de Almeida; Bruna Visniauskas; Guiomar Nascimento Gomes; Aparecida Emiko Hirata; Valquiria Bueno
Journal:  Clinics (Sao Paulo)       Date:  2013-06       Impact factor: 2.365

Review 6.  Trial Watch: Toll-like receptor agonists for cancer therapy.

Authors:  Erika Vacchelli; Alexander Eggermont; Catherine Sautès-Fridman; Jérôme Galon; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-06-10       Impact factor: 8.110

7.  Cancer-derived immunoglobulin G promotes LPS-induced proinflammatory cytokine production via binding to TLR4 in cervical cancer cells.

Authors:  Juping Wang; Danyi Lin; Hui Peng; Jimin Shao; Jiang Gu
Journal:  Oncotarget       Date:  2014-10-30

Review 8.  Application potential of toll-like receptors in cancer immunotherapy: Systematic review.

Authors:  Ming Shi; Xi Chen; Kangruo Ye; Yuanfei Yao; Yu Li
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

9.  Investigation into Cellular Glycolysis for the Mechanism Study of Energy Metabolism Disorder Triggered by Lipopolysaccharide.

Authors:  Ruyuan Zhang; Jian Ji; Ivana Blaženović; Fuwei Pi; Tingwei Wang; Yinzhi Zhang; Xiulan Sun
Journal:  Toxins (Basel)       Date:  2018-10-29       Impact factor: 4.546

10.  Procyanidin Compound (PC) Suppresses Lipopolysaccharide-Induced Cervical Cancer Cell Proliferation Through Blocking the TLR4/NF-κB Pathway.

Authors:  Haiyan Yang; Ziyu Fang; Xiaoli Qu; Xiaoli Zhang; Yifeng Wang
Journal:  Cancer Manag Res       Date:  2020-01-22       Impact factor: 3.989

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.